NCT02716805 2022-10-12
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Ludwig Institute for Cancer Research
Phase 1 Terminated
Ludwig Institute for Cancer Research
Institut Claudius Regaud
Duke University